Citations

Clear

1526 citation(s) found for "Sun, Yu".

Efficacy of Montelukast–Antihistamine Combination Therapy Versus Antihistamine Monotherapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis
Kim, Ji‐Sun , Stybayeva, Gulnaz , Hwang, Se Hwan , Stybayeya, Gulnaz , Hwang, Se Hwan

Mayo Clinic

Clinical and Experimental Otorhinolaryngology | September 17, 2025 | Volume: 19 | Issue: 2 | Pages: 164-176

10.21053/ceo.2025-00201 | PMID 40961985 Get It

Objectives. Allergic rhinitis (AR) can substantially compromise daily functioning and well-being, and many patients require more than a single agent to obtain satisfactory symptom control. This study examined whether adding montelukast to antihistamine could manage AR symptoms and quality-of-life outcomes effectively.Methods. A review was performed in PubMed, Embase, Medline, Scopus, the Cochrane Library, and Google Scholar to identify eligible studies reported through April 2025. Eligible studies compared combination therapy with montelukast plus antihistamine against antihistamine monotherapy and reported nasal symptoms or rhinoconjunctivitis quality of life questionnaire (RQLQ) scores. Treatment effects were further examined by antihistamine class.Results. Fifteen studies including 2,882 subjects were analyzed. Combination therapy significantly improved daytime nasal symptoms (standardized mean difference [SMD] [95% CI], 0.44 [0.21–0.67]), nighttime nasal symptoms (0.12 [0.01–0.23]), and RQLQ scores (0.14 [0.00–0.27]) versus monotherapy. Individual nasal or ocular symptoms, sneezing, nasal obstruction, and rhinorrhea improved significantly, while nasal itching and ocular symptoms did not. Combinations with desloratadine and levocetirizine showed greater benefits than those with loratadine or fexofenadine.Conclusion. Montelukast–antihistamine combination therapy reduced overall symptoms and improved quality of life versus antihistamine monotherapy. The magnitude of benefit appears to vary depending on the specific antihistamine used, highlighting the possible value of individualized treatment strategies in the treatments of AR.
A structured training curriculum for robot‐assisted radical nephroureterectomy: a Delphi consensus study
Sayyid, Rashid K. , Wu, Zhenjie , Antonelli, Alessandro , Guo, Shengjie , Hung, Andrew J. , Ma, Lulin , Margulis, Vitaly , Mehrazin, Reza , Porter, James , Potretzke, Aaron M. , Seisen, Thomas , Stein, Robert J. , Wang, Long , Wu, Jitao, Xylinas, Évanguelos , Djaladat, Hooman , Sayyid, Rashid K , Wu, Zhenjie , Abdollah, Firas , Antonelli, Alessandro , Ma, Lulin , Margulis, Vitaly , Matin, Surena F. , Potretzke, Aaron, Simone, Giuseppe , Wang, Long , Autorino, Riccardo , Djaladat, Hooman , Ghoreifi, Alireza , Moghaddam, Farshad Sheybaee , Ghoreifi, Alireza , Abdollah, Firas , Eun, Daniel , Ma, Lulin , Pradère, Benjamin , Rouprêt, Morgan , Shariat, Shahrokh F. , Simone, Giuseppe , Yao, Lin Xin , Zargar, Homayoun S. , Autorino, Riccardo , Cacciamani, Giovanni

Mayo Clinic

BJU International | September 17, 2025 | Volume: 136 | Issue: 6 | Pages: 1114-1120

10.1111/bju.70000 | PMID 40960222 Get It

Objectives To develop an internationally validated, structured robot‐assisted radical nephroureterectomy (RARNU) training programme through expert consensus. Materials and Methods A RARNU‐specific questionnaire was developed/adapted from previously published, validated questionnaires for robot‐assisted urological procedures. This included five key domains and 11 surgical steps. In all, 30 upper tract urothelial carcinoma experts were invited to participate. A two‐stage modified Delphi approach was employed. Consensus was defined as ≥80% agreement. Modifications and additional statements were proposed during the second round following qualitative/quantitative feedback from the initial round. Results Response rates for the first and second Delphi rounds were 80% (24/30) and 92% (22/24), respectively. All agreed that adoption of a standardised training curriculum can improve clinical outcomes during the RARNU learning curve. There was ≥92% agreement on all proposed RARNU steps. Five RARNU clinical modules of increasing complexity were defined using individual step difficulty and number of prior RARNU cases required, with ≥96% agreement among respondents. Respondents unanimously agreed that the final assessment should be based on a procedure‐specific scale focusing on the hilar dissection, ureteric dissection, and bladder cuff excision steps. No consensus was reached for the annual minimum RARNU volume required for eligibility as a RARNU curriculum host centre. Conclusion This is the first structured training curriculum for RARNU using international expert consensus. This will help guide surgical educators and trainees toward independent completion of a full RARNU.
AAPM TG report 330: EPID‐based quality assurance of linear accelerators
Sun, Baozhou, Yaddanapudi, Sridhar, Mutic, Sasa, Shi, Chengyu, McCurdy, Boyd M. C., Popple, Richard A., Lu, Minghui, Kim, Taeho, Clark, Jennifer R, Greer, Peter B, Yaddanapudi, Sridhar , Yaddanapudi, Sridhar , Sun, Baozhou, Mutic, Sasa, Shi, Chengyu, McCurdy, Boyd M. C., Popple, Richard A., Lu, Minghui, Kim, Taeho, Clark, Jennifer R, Greer, Peter B.

Mayo Clinic

Medical Physics | September 13, 2025 | Volume: 52 | Issue: 9 | Pages: No page available

10.1002/mp.18114 Get It

Abstract Electronic portal imaging devices (EPIDs) have been in widespread clinical use for almost two decades due to favorable measurement characteristics such as fast image acquisition, high sensitivity and resolution, digital data format, long‐term stability, linear dose response, and large detection area. On‐board EPIDs are widely used as a quality assurance (QA) tool to monitor nearly every aspect of linear accelerator (linac) performance. In both the commercial QA equipment market and in clinical practice, there is a trend toward replacing conventional QA approaches with fully automated, EPID‐based QA tools. Despite widespread use, EPIDs are complex devices, and there has yet to be consensus or formal recommendations published by the AAPM for their use in routine linac QA. Task Group 330 (TG‐330) was, therefore, formed to provide guidelines and recommendations for physicists on the safe and appropriate use of EPIDs for linac QA. In particular, the report: (a) provides a comprehensive review of the characteristics and limitations of EPIDs as time‐resolved measurement devices and dosimeters; (b) summarizes the application of EPIDs for linac QA; (c) provides recommendations on efficient and effective implementations of EPID‐based QA techniques; (d) describes risks associated with the use of EPIDs for linac QA and provides examples of how risk analysis can be used to ensure the safe use of EPIDs for linac QA. Many of the guidelines in this report are drawn from the literature that is included in the references and from the collective experience of the task group members. This report does not provide recommendations on the implementation of EPID‐based patient‐specific IMRT or VMAT QA, which is the topic of AAPM's report from AAPM TG‐307.
Abnormal ERV Expression and Its Clinical Relevance in Colon Cancer
Bhagwate, Aditya , Taylor, William R. , Kisiel, John B. , Sun, Zhifu , Kisiel, John B , Sun, Zhifu

Mayo Clinic

Genes | August 22, 2025 | Volume: 16 | Issue: 8 | Pages: 988

10.3390/genes16080988 | PMID 40870036 Get It

Background/Objectives: Human endogenous retroviruses (ERVs) are genomic sequences integrated into the human genome from ancestral exogenous retroviruses and are epigenetically silenced under normal conditions. Growing evidence has shown that they can be reactivated in human diseases such as cancers and autoimmune diseases. However, their clinical implications in colon cancer are yet to be explored. Methods: RNA-seq data were downloaded from RNA Atlas and TCGA for cell lines and tissue samples, respectively. After alignment, ERV expression was quantified against comprehensively compiled ERVs (3220). ERV expression profiles were compared between sequencing protocols, cancer and normal cells, and matched tumor and normal tissue pairs. Unsupervised clustering was used to identify ERV-defined tumor subtypes and their associations with clinical and other molecular features. ERV association with disease-specific survival (DSS) was performed using the Cox regression model. Results: PolyA and total RNA protocols were comparable in ERV expression detection. Cancer cells had significantly increased ERV expression and reactivation. Upregulated ERVs were significantly enriched in viral protein interactions with cytokine and cytokine receptors. ERV expression-defined tumor classes were significantly associated with tumor mutation burden and immuno-phenotypes such as antigen processing and presenting machinery and tumor immune infiltration score. Survival analysis identified 152 ERVs to be independently associated with DSS. Conclusions: ERV abnormal expression is common in colon cancer. The ERV-defined subtypes are associated with tumor immunity, and some ERVs are independently associated with patient outcomes.
Cerebellum mitochondrial DNA copy number is increased in Parkinson’s disease
Beglarian, Talia , Tyrpak, David R. , MacKay, J. Andrew , Scholz, Sonja W. , Albert, Marilyn S. , Dawson, Ted M. , Troncoso, Juan C. , Hernandez, Dena G., Cookson, Mark R , Singleton, Andrew B., Beach, Thomas G., Hjelm, Brooke E. , MacKay, John Andrew , Scholz, Sonja W , Dawson, Ted M , Cookson, Mark , Adler, C H , Serrano, Geidy E , Hjelm, Brooke E , Gibbs, J. Raphael , Traynor, Bryan J , Rosenthal, Liana S. , Adler, Charles H. , Serrano, Geidy E. , Singleton, Andrew B., Beach, Thomas G.

Mayo Clinic

Brain Communications | August 20, 2025 | Volume: 7 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcaf296 | PMID 40873892 Get It

Abstract Bioinformatics methods can be used to quantify mitochondrial DNA copy number from whole genome sequencing (WGS) data. We evaluated mitochondrial DNA copy number from human brain-derived WGS data using the fastMitoCalc tool. 341 Parkinson’s Disease cerebellum samples were compared with 74 age-matched controls from the North American Brain Expression Consortium. Parkinson’s Disease cerebellum had significantly higher mitochondrial DNA copy number compared with controls (P = 4.15e–7), and this effect was reproducible in four of five brain banks when analysis was restricted to each resource that contributed Parkinson’s Disease samples to this genetic dataset. Follow-on analyses of 128 Parkinson’s Disease cerebellum samples and 33 controls that had paired neuropathology data and clinical scores demonstrated a significant increase in mitochondrial DNA copy number with Unified Staging System for Lewy Body disorders stages and Unified Parkinson’s Disease Rating Scale (off meds) motor scores. Analysis of Lewy Body scores from ten brain regions showed cerebellum mitochondrial DNA copy number increased upon pathological infestation of α-synuclein aggregates in the brainstem and limbic system but did not increase after late-stage neocortical involvement. This genetics dataset supports previous observations of cerebellum activation in Parkinson’s Disease and suggests mitochondrial DNA copy number may increase to support this regional activation as a compensatory mechanism to pathology or motor symptoms.
Treg-specific IL-6R signaling: a novel role in the regulation of the intestinal epithelium
Klatt, Emily, Hamdan, Feda H. , Pérez, Isaiah , Kossick, Kimberlee , Fedyshyn, Yaroslav , Sagstetter, Mary R., Chiang, David , Chini, Lucas C. S., Davidson, H, Westphal, Maria S., Gades, Naomi M. , Mopuri, Rohini , Druliner, Brooke R. , Faubion, William A. , Klatt, Emily E, Smith, Hannah M , Kossick, Kimberlee , Davidson, Heidi M, Bamidele, Adebowale O , Druliner, Brooke , Chini, Lucas C. S., Sun, Zhifu , Bamidele, Adebowale O.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | August 18, 2025 | Volume: 329 | Issue: 6 | Pages: G696-G707

10.1152/ajpgi.00131.2025 | PMID 40820933 Get It

This study reveals a novel role for Treg-derived IL-6R in supporting epithelial repair. Despite preserved immune-suppressive capacity, deletion of IL-6R from Tregs impairs epithelial transcription and worsens injury in colitis. We demonstrate that human intestinal organoids preferentially respond to trans- over classic IL-6 signaling. These findings introduce a Treg-specific role in immune-epithelial cross talk relevant to mucosal healing and inflammatory bowel disease.
Recognition and Management of Iatrogenically Induced Opioid Dependence and Withdrawal in Children: Clinical Report
Siegel, Linda, Wilder, Robert T. , Good, Julie , Reigart, J. Routt, Eckstein, Olive S. , Hindman, Diane E., Verhoef, Philip A. , Watt, Kevin , Care, Section on Critical, Hsu, Benson, Huh, Jimmy W. , Lowrie, Lia, Ndely, Simon-Noel, Satchell, Margaret A., Medicine, Section on Anesthesiology and Pain, Chatterjee, Debnath , Diaz, Christina, Drum, Elizabeth T. , Sun, Lena S. , Willer, Brittany L. , Landrigan‐Ossar, Mary, Adler, Adam C. , Goldman, Jennifer L. , Hindman, Diane E., Care, Section on Critical, Ndely, Simon-Noel, Srinivasan, Vijay , Medicine, Section on Anesthesiology and Pain, Long, Justin B.

Mayo Clinic

Pediatrics | August 18, 2025 | Volume: 156 | Issue: 3 | Pages: No page available

10.1542/peds.2025-073169 | PMID 40819838 Get It

Opioids are often prescribed to children for pain relief related to procedures, acute injuries, and chronic conditions. Around-the-clock dosing of opioids can produce physiologic opioid dependence within 5 days. According to a 2001 consensus paper from the American Academy of Pain Medicine, American Pain Society, and American Society of Addiction Medicine, dependence is defined as “a state of adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, or administration of an antagonist.” The experience of children undergoing iatrogenic withdrawal symptoms is variable and may be mild and go unreported or can be severe and even life threatening. Guidance on opioid withdrawal is available only for adults and primarily for adults with substance use disorders. This report will summarize existing literature and provide readers with information on how to screen for symptoms of iatrogenic opioid withdrawal as well as mechanisms for opioid withdrawal prevention.
Impact of Advanced Heart Failure Duration on Left Ventricular Functional Improvement After Left Ventricular Assist Device Implantation
Crespo‐Diaz, Ruben , Sun, Benjamin , McDonald, William C. , Weaver, C.E. , Samara, Michael A., Hryniewicz, Katarzyna , McDonald, William, Eckman, Peter

Mayo Clinic

ASAIO Journal | July 31, 2025 | Volume: 72 | Issue: 7 | Pages: 562-569

10.1097/mat.0000000000002474 | PMID 40742196 Get It

Left ventricular recovery (LV) in patients with advanced heart failure (HF) supported by a durable left ventricular assist device (LVAD) is uncommon but clinically significant. There is limited understanding on the timing of LV recovery in relation to LVAD implantation. A total of 383 HF patients who underwent LVAD implantation were evaluated for LV functional improvement defined as an absolute increase in left ventricular ejection fraction (LVEF) of greater than or equal to 20% post-LVAD placement. Out of 383 LVAD patients, 39 (10.1%) demonstrated significant LV improvement. Among these, 25 (64%) patients had received LVAD less than or equal to 1 year of HF diagnosis, whereas 14 (36%) patients were implanted greater than 1 year from HF diagnosis. No significant differences in baseline imaging or hemodynamics were found between these two groups. The timing of LVAD implantation and time from LVAD to LVEF improvement was not associated with 5 year outcomes. Survival, free from HF relapse or transplant was 59% in the less than or equal to 1 year and 46% in greater than 1 year HF duration groups ( p = 0.83). Thus, LV functional improvement can occur across a broad spectrum of HF duration, suggesting that the potential for recovery is not limited to those with newly diagnosed disease.
Teleportation: Defense Against Stealing Attacks of Data-Driven Healthcare APIs
Wang, Zhenyi , Shen, Li , Luan, Siyu , Li, Fang , Doretto, Gianfranco , Adjeroh, Donald , Niu, Shuteng , Li, Jianfu , Tao, Cui , Tao, Cui , Niu, Shuteng , Li, Jianfu , Li, Fang , Duan, Tiehang , Shen, Li , Luan, Siyu

Mayo Clinic

IEEE Transactions on Artificial Intelligence | July 29, 2025 | Volume: 7 | Issue: 3 | Pages: 1273-1289

10.1109/tai.2025.3593470 Get It